Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Indian J Med Paediatr Oncol
2016 Jan 01;374:242-250. doi: 10.4103/0971-5851.195735.
Show Gene links
Show Anatomy links
Clinicopathological features and outcomes in advanced nonsmall cell lung cancer with tailored therapy.
Bala S
,
Gundeti S
,
Linga VG
,
Maddali LS
,
Digumarti RR
,
Uppin SG
.
???displayArticle.abstract???
CONTEXT: Lung cancer is an important cause of cancer-related deaths worldwide. There is an increasing incidence of lung cancer in never smokers and a shift of histology from squamous cell to adenocarcinoma globally in the recent past. Data on treatment outcomes with newer platinum doublets is scant from India.
AIMS: To study the clinicopathological features, response rates (RRs), progression-free survival (PFS), overall survival (OS), and the 1, 2, and 3 years survival, in patients with advanced nonsmall cell lung cancer (NSCLC).
MATERIALS AND METHODS: Data of all patients who received chemotherapy for Stage IIIB and IV NSCLC between January 2010 and June 2014 were retrospectively analyzed.
STATISTICAL ANALYSIS USED: Univariate analysis for OS was done by plotting Kaplan-Meier curves and the log-rank test was used to calculate P values. Logistic regression analysis for OS was carried out using MedCalc statistical software.
RESULTS: A total of 353 patients received chemotherapy. Of these, 256 were evaluable for outcome parameters. The median age at presentation was 58 years with a male:female ratio of 2.53:1. The smoker:nonsmoker ratio was 1:1. Adenocarcinomatous histology was the most common both in smokers and nonsmokers reported in 70.8% patients. Epidermal growth factor receptor (EGFR) mutation and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase translocation were seen in 35% and 3% of patients, respectively. The RR, median PFS, OS, 1, 2, and 3 years survival were 80%, 8 months, 12.1 months, 51.5%, 12.7%, and 4.2%, respectively. There was no significant survival difference among the treatment regimen used but the response to I line chemotherapy impacted survival. Female gender, performance status, and nonsquamous histology were significant predictors of OS (P = 0.0443, P = 0.0003, P = 0.048, respectively).
CONCLUSIONS: There was an increase in the incidence of nonsmokers. Adenocarcinoma was the most common histology in both smokers and nonsmokers. Treatment outcomes in advanced lung cancer were better compared to the past with the advent of newer platinum doublets and EGFR tyrosine kinase inhibitors. The response to first-line chemotherapy significantly impacts outcomes in advanced NSCLC.
Behera,
Lung cancer in India.
2004,
Pubmed
Bhatt,
Clinicopathologic features of non-small cell lung cancer in India and correlation with epidermal growth factor receptor mutational status.
2013,
Pubmed
Choughule,
Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients.
2013,
Pubmed
Devesa,
International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising.
2005,
Pubmed
Dey,
Comparison study of clinicoradiological profile of primary lung cancer cases: an Eastern India experience.
2012,
Pubmed
Doval,
Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung.
2015,
Pubmed
,
Echinobase
Eisenhauer,
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
2009,
Pubmed
Gao,
Lung cancer among Chinese women.
1987,
Pubmed
Goldstraw,
The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.
2007,
Pubmed
Jemal,
Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control.
2008,
Pubmed
Jindal,
Bronchogenic carcinoma in Northern India.
1982,
Pubmed
Johnson,
Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis.
2006,
Pubmed
Kanavos,
The rising burden of cancer in the developing world.
2006,
Pubmed
Krishnamurthy,
The relevance of "Nonsmoking-associated lung cancer" in India: a single-centre experience.
2012,
Pubmed
Kwak,
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
2010,
Pubmed
Maemondo,
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
2010,
Pubmed
Mehta,
Molecular epidemiology of epidermal growth factor receptor mutations in lung cancers in Indian population.
2013,
Pubmed
Mok,
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
2009,
Pubmed
Noronha,
Epidemiology of lung cancer in India: focus on the differences between non-smokers and smokers: a single-centre experience.
2012,
Pubmed
Rajappa,
Chemotherapy for advanced lung cancer: a 5-year experience.
2008,
Pubmed
Rosell,
Screening for epidermal growth factor receptor mutations in lung cancer.
2009,
Pubmed
Samet,
Lung cancer in never smokers: clinical epidemiology and environmental risk factors.
2009,
Pubmed
Scagliotti,
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
2008,
Pubmed
Sequist,
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
2008,
Pubmed
Sequist,
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
2007,
Pubmed
Shimizu,
Comparison of clinico-epidemiological features of lung cancer patients with and without a history of smoking.
1984,
Pubmed
Siegel,
Cancer statistics, 2013.
2013,
Pubmed
Sirohi,
Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival.
2007,
Pubmed
Socinski,
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
2012,
Pubmed
Toh,
Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity.
2006,
Pubmed
Veldore,
Epidermal growth factor receptor mutation in non-small-cell lung carcinomas: a retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in India.
2013,
Pubmed
